 |
Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin(R) in Recurrent, Metastatic Non-Small Cell Lung Cancer
Jun 1, 2007
|
14.1 KB |
|
| |
CHICAGO and SUNNYVALE, Calif. June 1, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced promising preliminary results from an open-label Phase 2 clinical trial of Xcytrin(R) (motexafin gadolinium) Injection, the company's lead cancer therapeutic candidate, as a second-line treatment for patien...
|
|
Pharmacyclics to Present at the 2007 Friedman Billings Ramsey Growth Conference
May 30, 2007
|
9.0 KB |
|
| |
SUNNYVALE, Calif., May 30, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that Richard A. Miller, M.D., president and chief executive officer, will make a company presentation at the 2007 Friedman Billings Ramsey Growth Conference on Thursday, May 31st, at 9:00 a.m. EDT at The Grand Hyatt i...
|
|
Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
May 23, 2007
|
10.1 KB |
|
| |
SUNNYVALE, Calif., May 23, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today multiple presentations and a published abstract regarding Xcytrin(R) (motexafin gadolinium) Injection, including an oral presentation of Phase 3 SMART (Study of Neurologic Progression with Motexafin Gadolinium And Rad...
|
|
Pharmacyclics Announces Appointment of Michael K. Inouye as Senior Vice President of Corporate and Commercial Development
May 8, 2007
|
8.8 KB |
|
| |
SUNNYVALE, Calif., May 8, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the appointment of Michael K. Inouye as Senior Vice President of Corporate and Commercial Development.
Mr. Inouye has over 25 years of experience in the pharmaceutical industry in sales, marketing and business deve...
|
|
Pharmacyclics Reports Third Quarter Financial Results and Corporate Update
Apr 26, 2007
|
14.5 KB |
|
| |
SUNNYVALE, Calif., April 26, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its third fiscal quarter ended March 31, 2007. The net loss for the third quarter of fiscal 2007 was $6.8 million, or $0.26 per share, compared to a net loss of $7.4 million, or $0.37 per share,...
|
|
Pharmacyclics Announces FDA Filing of New Drug Application for Xcytrin(R) Injection to Treat Lung Cancer Brain Metastases
Apr 23, 2007
|
13.6 KB |
|
| |
SUNNYVALE, Calif., April 23, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has filed the company's New Drug Application (NDA) for Xcytrin(R) (motexafin gadolinium) Injection. The Prescription Drug User Fee Act (PDUFA) date for completion of ...
|
|
Pharmacyclics Announces Conference Call to Discuss Third Quarter 2007 Financial Results
Apr 19, 2007
|
8.6 KB |
|
| |
SUNNYVALE, Calif., April 19, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it will hold a conference call to discuss its third quarter 2007 financial results and achievements on Thursday, April 26, 2007, at 4:30 p.m. EDT (1:30 p.m. PDT).
To participate in the conference call, plea...
|
|
Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Bruton's Tyrosine Kinase Inhibitors
Apr 18, 2007
|
12.9 KB |
|
| |
SUNNYVALE, Calif. and LOS ANGELES, April 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced data from two preclinical studies, one identifying a functional biomarker for its novel histone deacetylase (HDAC) inhibitor and another demonstrating preclinical anti-tumor activity with its Bruton'...
|
|
Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds
Apr 11, 2007
|
11.4 KB |
|
| |
SUNNYVALE, Calif., April 11, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today multiple presentations regarding its novel histone deacetylase (HDAC) inhibitor and Bruton's tyrosine kinase inhibitor compounds. The presentations will take place at the American Association for Cancer Research (AA...
|
|
Pharmacyclics' Xcytrin New Drug Application for Treatment of Lung Cancer Brain Metastases to Be Filed Over Protest
Apr 4, 2007
|
14.6 KB |
|
| |
SUNNYVALE, Calif., April 4, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced its request to the U.S. Food and Drug Administration (FDA) that its New Drug Application (NDA) for Xcytrin(R) (motexafin gadolinium) Injection be filed over protest. The NDA seeks approval to market the drug for the ...
|
|
Pharmacyclics to Host Conference Call on Wednesday, April 4, 2007
Apr 3, 2007
|
8.3 KB |
|
| |
SUNNYVALE, Calif., April 3, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it will hold a conference call on Wednesday, April 4, 2007, at 9:00 a.m. EST (6:00 a.m. PST) to discuss company news.
To participate in the conference call, please dial 800-497-0451 for domestic callers and ...
|
|
Pharmacyclics to Present at Cowen and Company Health Care Conference
Mar 8, 2007
|
8.4 KB |
|
| |
SUNNYVALE, Calif., March 8, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that Richard A. Miller, M.D., president and CEO, will present at the Cowen and Company Annual Health Care Conference on Thursday, March 15, 2007 at 11:00 a.m. ET at The Boston Marriott Copley Place Hotel in Boston, M...
|
|
Pharmacyclics Receives Refuse to File Letter for Xcytrin
Feb 21, 2007
|
12.2 KB |
|
| |
SUNNYVALE, Calif., Feb 21, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has received a refuse to file letter from the U.S. Food and Drug Administration (FDA) for the company's new drug application (NDA) for Xcytrin(R) (motexafin gadolinium) Injection for the treatment of non-small...
|
|
Pharmacyclics Reports Second Quarter Financial Results and Corporate Update
Jan 25, 2007
|
14.2 KB |
|
| |
SUNNYVALE, Calif., Jan 25, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its second fiscal quarter ended December 31, 2006. The net loss for the second quarter of fiscal 2007, as reported in accordance with U.S. generally accepted accounting principles (GAAP), was $6.0...
|
|
Pharmacyclics Announces Conference Call to Discuss Second Quarter 2007 Financial Results
Jan 18, 2007
|
8.4 KB |
|
| |
SUNNYVALE, Calif., Jan 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it will hold a conference call to discuss its second quarter 2007 financial results and achievements on Thursday, January 25, 2007, at 4:30 p.m. EDT (1:30 p.m. PDT).
To participate in the conference call, ple...
|
|
Pharmacyclics Submits New Drug Application for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Dec 22, 2006
|
11.7 KB |
|
| |
SUNNYVALE, Calif., Dec 22, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has submitted a New Drug Application (NDA) for Xcytrin(R) (motexafin gadolinium) Injection with the U.S. Food and Drug Administration (FDA). The company is seeking approval to market Xcytrin for the treatment ...
|
|
Pharmacyclics Announces Preclinical Data Publication Indicating Potential Use of Its Novel Selective B-Cell Tyrosine Kinase Inhibitor Compounds in Autoimmune Diseases and Lymphomas
Dec 13, 2006
|
11.8 KB |
|
| |
SUNNYVALE, Calif., Dec 13, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the publication of data characterizing its novel compounds designed to inhibit Bruton's Tyrosine Kinase (Btk). Btk is a tyrosine kinase signaling molecule expressed in multiple immune cell types, including B-cells, ma...
|
|
Pharmacyclics to Present at the 2006 RBC Capital Markets Healthcare Conference
Dec 7, 2006
|
8.4 KB |
|
| |
SUNNYVALE, Calif., Dec 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that Richard A. Miller, M.D., president and chief executive officer, will participate on the "Hot New Targets In Cancer" panel on Wednesday, December 13th at 12:30 p.m. as part of the 2006 RBC Capital Markets Healthca...
|
|
Pharmacyclics Announces Presentation of Pooled Analysis of Xcytrin(R) for Lung Cancer Brain Metastases
Nov 20, 2006
|
13.0 KB |
|
| |
SUNNYVALE, Calif., Nov 20, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the presentation of pooled results from two randomized Phase 3 clinical trials, which indicate that Xcytrin(R) (motexafin gadolinium) Injection combined with whole brain radiation therapy (WBRT) significantly prolonge...
|
|
Pharmacyclics Announces Underwriters' Exercise of Over-Allotment Option
Nov 16, 2006
|
8.1 KB |
|
| |
SUNNYVALE, Calif., Nov 16, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the underwriters of their previously announced underwritten public offering of 4,200,000 shares of common stock have exercised their option to purchase the entire over-allotment consisting of 630,000 shares of co...
|
|
|
